Life sciences employer

Vividion Therapeutics

2 open positions1 remote-friendly

What Vividion Therapeutics is hiring for

2 active

Claim to unlock

Mission, culture, and benefits - visible once this page is claimed and verified.

Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer

Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers

Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry

Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology

A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth

Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2